Skip to content

Author

Mazen Hanna

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Amyloidosis & Advanced Heart Failure: When to Consider Cardiac Transplantation and What are the Results?

The management of end-stage heart failure in cardiac amyloidosis due to both light chain (AL-CA) and transthyretin (ATTR-CA) with heart transplantation has historically been limited by concerns about systemic progression after transplant. As a result, heart transplantation as a strategy was often restrictive and many p...

Steven A. Hamilton, Harsh H. Patolia, Mazen Hanna · 0 citations
Review Open access Sep 2026

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy

Disease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) improve clinical outcomes, yet older patients are undertreated. In this analysis, we evaluated survival and cardiovascular-related hospitalizations (CVH) among patients treated with tafamidis (tafamidis free acid at 61 mg or bioequivalent ta...

C. Fumagalli, F. Cappelli, M. Maurer et al. · 0 citations
Review Open access Aug 2026

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis and support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.

S. Dorbala, Mathew S. Maurer, S. Cuddy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.